OSCR 📈 Oscar Health - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6877931096

OSCR: Health Insurance, Reinsurance, Technology Platform

Oscar Health Inc, listed on the New York Stock Exchange as OSCR, is a key player in the US health insurance market, offering a range of plans tailored for individuals and small groups. The company's product portfolio is complemented by +Oscar, a cutting-edge platform designed to facilitate the transition to value-based care for both healthcare providers and payors. This platform leverages technology to streamline processes, enhance care coordination, and ultimately improve patient outcomes. Additionally, Oscar Health provides reinsurance products, further expanding its footprint in the health insurance sector.

With its roots dating back to 2012, Oscar Health has undergone significant evolution, including a name change from Mulberry Health Inc. to its current moniker in January 2021. This transformation reflects the company's growth and its commitment to innovating within the health insurance landscape. Headquartered in New York, New York, Oscar Health operates with a strong online presence, accessible through its website at https://www.hioscar.com. The company's common stock is traded under the ISIN code US6877931096, categorized under the Life & Health Insurance sub-industry within the GICS classification system.

Oscar Health's business model is built around providing affordable, high-quality health insurance plans that cater to the diverse needs of its customers. By integrating technology and data analytics into its core operations, the company aims to reduce healthcare costs, enhance the patient experience, and foster a more efficient healthcare delivery system. The +Oscar platform is a testament to this approach, offering a suite of tools and services that support value-based care initiatives, including care management, network development, and population health analytics. As the healthcare industry continues to shift towards more personalized and cost-effective care models, Oscar Health is well-positioned to play a significant role in this transformation.

Additional Sources for OSCR Stock

OSCR Stock Overview

Market Cap in USD 4,092m
Sector Healthcare
Industry Healthcare Plans
GiC Sub-Industry Life & Health Insurance
IPO / Inception 2021-03-03

OSCR Stock Ratings

Growth 5y -41.4%
Fundamental 0.49%
Dividend -
Rel. Strength Industry 60.4
Analysts 3.83/5
Fair Price Momentum 12.56 USD
Fair Price DCF 83.03 USD

OSCR Dividends

No Dividends Paid

OSCR Growth Ratios

Growth Correlation 3m -66.9%
Growth Correlation 12m 29%
Growth Correlation 5y -0.1%
CAGR 5y -21.42%
CAGR/Mean DD 5y -0.31
Sharpe Ratio 12m 0.86
Alpha 8.65
Beta 1.69
Volatility 73.39%
Current Volume 2032.3k
Average Volume 20d 4163.5k
What is the price of OSCR stocks?
As of December 30, 2024, the stock is trading at USD 13.80 with a total of 2,032,318 shares traded.
Over the past week, the price has changed by +1.47%, over one month by -20.37%, over three months by -34.94% and over the past year by +50.82%.
Is Oscar Health a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Oscar Health is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 0.49 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of OSCR as of December 2024 is 12.56. This means that OSCR is currently overvalued and has a potential downside of -8.99%.
Is OSCR a buy, sell or hold?
Oscar Health has received a consensus analysts rating of 3.83. Therefor, it is recommend to buy OSCR.
  • Strong Buy: 2
  • Buy: 2
  • Hold: 1
  • Sell: 1
  • Strong Sell: 0
What are the forecast for OSCR stock price target?
According to ValueRays Forecast Model, OSCR Oscar Health will be worth about 14.2 in December 2025. The stock is currently trading at 13.80. This means that the stock has a potential upside of +2.9%.
Issuer Forecast Upside
Wallstreet Target Price 19.4 40.3%
Analysts Target Price 8.7 -37.2%
ValueRay Target Price 14.2 2.9%